Back to Agenda
Session 2: Navigating The Evolving Global Pharmacovigilance Regulatory Landscape
Session Chair(s)
Willemijn van der Spuij, MSc
Executive Director Europe | International - Patient Safety, Bristol Myers Squibb, Switzerland
Birgit Van De Vliet
Senior Director Global Safety, EU Deputy QPPV , GSK, Belgium
Session Overview: This session will provide a strategic overview of the evolving global pharmacovigilance regulatory landscape, highlighting recent updates, emerging regulatory trends, and forthcoming requirements across key jurisdictions. Participants will gain insight into recent developments, forthcoming regulatory changes, and how these evolving requirements are redefining compliance expectations, with particular emphasis on the practical implications for QPPVs.
Speaker(s)
Priya Bahri, PhD
Senior Lead (Pharmacovigilance and Risk Management Guidance and Policy), European Medicines Agency, Netherlands
Key international regulatory developments impacting QPPVs globally
Pat Harding
Sr. Director - GPS Office of the QPPV, Operations/PSMF, Global Patient Safety, Eli Lilly and Company, United Kingdom
Emerging Trends from MENA region and Strategic Impact on QPPV
Rory Littlebury
Head of PVSO and QPPV Office, GlaxoSmithKline (GSK), United Kingdom
Have an account?